The White House recently imposed sweeping new tariffs on a wide variety of imported goods.

The good news for patients is that pharmaceutical products are not subject to these so-called "reciprocal tariffs" -- for now. But that soon may change, as President Donald Trump has suggested that we'll still see pharma-specific tariffs "at some point."

Trump seems to expect this threat will force companies to move pharmaceutical manufacturing to the U.S. overnight. But in reality, upending longstanding global supply chains to shift manufacturing for even one product is a long-term, costly endeavor. It's one that also requires a well-staffed and resourced FDA to authorize each aspect of tech transfer and manufacturing scale-up.

With the continued cuts at the FDA and a larger brain drain expected to come, manufacturers are rightly concerned that the typical five-year timeline for building and operating new manufacturing sites would........

© International Business Times